LipoCol Forte capsules reduce the risk of liver cancer: A propensity score-matched, nationwide, population-based cohort study

Table 1 Demographic characteristics and comorbidities for non-LipoCol Forte capsules users and LipoCol Forte capsules user populations in Taiwan between 2010 and 2017

Variables	Non-LFC users (n = 33231)		LFC users (n = 33231)		SMD
	n	%	n	%
Sex
Female	15869	47.75	15798	47.54	0.004
Male	17362	52.25	17433	52.46	0.004
Age (yr)
20-29	300	0.90	319	0.96	0.006
30-39	1434	4.32	1545	4.65	0.016
40-49	3677	11.07	3816	11.48	0.013
> 50	27820	83.72	27551	82.91	0.022
mean (SD)	63.22	13.60	62.75	13.62	0.035
Comorbidities
Hypertension	21195	63.78	20825	62.67	0.023
Coronary heart disease	11255	33.87	10972	33.02	0.018
Ischemic stroke	6902	20.77	6784	20.41	0.009
Hemorrhagic stroke	816	2.46	939	2.83	0.023
Diabetes mellitus	12348	37.16	12172	36.63	0.011
Hyperlipidemia	16793	50.53	16196	48.74	0.036
Renal insufficiency	4028	12.12	4007	12.06	0.002
Cirrhosis	2585	7.78	2643	7.95	0.007
Alcoholic liver damage	2554	7.69	2606	7.84	0.006
Nonalcoholic fatty liver disease	1648	4.96	1825	5.49	0.024
HBV infection	3239	9.75	3342	10.06	0.010
HCV infection	2061	6.20	2196	6.61	0.017
Medications
Statin	12008	36.13	11666	35.11	0.022
Non-statin lipid-lowering drug	6339	19.08	6161	18.54	0.014
Aspirin	15564	46.84	15330	46.13	0.014
HBV treatment	1531	4.61	1572	4.73	0.006
HCV treatment	7	0.02	10	0.03	0.006
Metformin	8674	26.10	8469	25.49	0.014
Thiazolidinediones	2533	7.62	2483	7.47	0.006

Student’s t-test. LFC: LipoCol Forte capsules; SMD: Standardized mean difference (a standardized mean difference of 0.05 or less indicates a negligible difference); SD: Standard deviation; HBV: Hepatitis B virus; HCV: Hepatitis C virus.